You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,201,584


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,201,584
Title:Compositions and methods for treating HCV
Abstract: This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.
Inventor(s): Collins; Christine A. (Skokie, IL), Cohen; Daniel E. (Highland Park, IL), Koev; Gennadiy (Libertyville, IL), Krishnan; Preethi (Gurnee, IL), Pilot-Matias; Tami J. (Green Oaks, IL)
Assignee: ABBVIE INC. (North Chicago, IL)
Application Number:14/247,975
Patent Claims: 1. A method for treating a subject infected with hepatitis C virus (HCV) genotype 1, said method comprising administering to said subject an amount of therapeutic agent A and an amount of therapeutic agent B, wherein therapeutic agent A is compound A or a salt thereof: ##STR00005## wherein therapeutic agent B is compound B or a salt thereof: ##STR00006## wherein the molar ratio of therapeutic agent A to therapeutic agent B is about 1:20 to about 1:2000, and wherein therapeutic agent A and therapeutic agent B are administered to the subject from the same pharmaceutical composition.

2. The method of claim 1, wherein the subject is a human.

3. The method of claim 1, wherein the total daily dosage amount of therapeutic agent A administered to the subject is about 25 mg.

4. The method of claim 1, wherein therapeutic agent B is a sodium salt of compound B.

5. The method of claim 1, wherein the method further comprises administering one or more additional therapeutic agents selected from the group consisting of interferon, ribavirin, taribavirin, and HCV inhibitor.

6. The method of claim 5, wherein the additional therapeutic agent is an HCV inhibitor.

7. The method of claim 6, wherein the HCV inhibitor is an HCV protease inhibitor.

8. The method of claim 5, wherein therapeutic agent A, therapeutic agent B, and the additional therapeutic agent are administered to the subject from the same pharmaceutical composition.

9. The method of claim 3, wherein the pharmaceutical composition is administered to the subject once is a 24-hour period.

10. The method of claim 7, wherein the method further comprises administering a cytochrome P-450 inhibitor.

11. The method of claim 10, wherein the cytochrome P-450 inhibitor is ritonavir.

12. The method of claim 1, wherein the total daily dosage of both therapeutic agent A and therapeutic agent B are administered to the subject within a twenty-four hour period.

13. The method of claim 12, wherein the pharmaceutical composition is administered once or twice daily.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.